A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
Status and phase
Completed
Phase 3
Conditions
Hypercholesterolemia
Type 2 Diabetes Mellitus
Treatments
Drug: Comparator: atorvastatin
Drug: Duration of Treatment: 4 wk placebo run in then 6 wk active
Drug: MK0653A, ezetimibe (+) simvastatin
Details and patient eligibility
About
The purpose of this 10-week study is to compare the reduction in cholesterol following treatment with two different marketed drugs, in patients with type 2 diabetes mellitus and hypercholesterolemia.
Enrollment
1,229 patients
Sex
All
Ages
18 to 79 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs.
Exclusion criteria
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus that is poorly controlled
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems